KLRC1 and acute myeloid leukemia: NKG2A-deficient NK cells had improved cytotoxic functionality in targeting HLA-E-expressing and HLA-E-deficient cancer cells deriving from Ewing’s sarcoma, osteosarcoma, and AML [12,111].